MedPath

ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study

Phase 3
Conditions
Hepatic Encephalopathy
Registration Number
NCT01798329
Lead Sponsor
A.O. Ospedale Papa Giovanni XXIII
Brief Summary

The aim of the study is:

* Epidemiological/observational: investigating the presence of neuropsychological and electrophysiological alterations, suggesting a condition of minimal hepatic encephalopathy(and its behavioral correlates), in childhood and young adulthood affected by pre-hepatic portal hypertension due to portal vein thrombosis, even for implementing specific diagnostic protocols.

* Interventional: collecting preliminary data on the effects of a probiotic, in order to implement a controlled clinical study.

Detailed Description

Epidemiological/observational study investigating the presence of neuropsychological and electrophysiological alterations, suggesting a condition of minimal hepatic encephalopathy(and its behavioral correlates), in childhood and young adulthood affected by pre-hepatic portal hypertension due to portal vein thrombosis, even for implementing specific diagnostic protocols

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • extra-hepatic portal vein thrombosis
  • 4-20 years
  • knowledge of italian language
  • absence of perceptive or communicative deficit
  • absence of psychiatric disease or mental retardation
Exclusion Criteria
  • medical contraindications for required evaluations
  • infective pathologies
  • parenchymal hepatic pathologies

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
neuropsychological and electrophysiological aspectsafter 15 weeks of probiotic or placebo treatment

Improvement in the spectrum of the digitalised electroencephalogram, improvement in the performance of the psychometric tests

Secondary Outcome Measures
NameTimeMethod
biochemical blood testafter 15 weeks of probiotic or placebo treatment

Decreased level of serum ammonia

urine and faeces analysisafter 15 weeks of probiotic or placebo treatment
abdomen scan with color doppler techniqueafter 15 weeks of probiotic or placebo treatment
neurological evaluationafter 15 weeks of probiotic or placebo treatment
dietary anamnesis (last three days)after 15 weeks of probiotic or placebo treatment
bowel frequency and characteristicsafter 15 weeks of probiotic or placebo treatment

Trial Locations

Locations (2)

Azienda Ospedaliera Papa Giovanni XXIII

🇮🇹

Bergamo, Italy

University of Padua

🇮🇹

Padova, Italy

Azienda Ospedaliera Papa Giovanni XXIII
🇮🇹Bergamo, Italy
Lorenzo D'Antiga, MD
Contact
+39 0352673856
ldantiga@hpg23.it
LORENZO D'ANTIGA, MD
Principal Investigator
MICHELA BRAVI, MD
Sub Investigator
VALERIA CASOTTI, MD
Sub Investigator
MARA COLUSSO, MD
Sub Investigator
MARCO PEZZANI, MD
Sub Investigator
LORELLA CAFFI, MD
Sub Investigator
EMILIO UBIALI, MD
Sub Investigator
MARIA SIMONETTA SPADA, PSYCHOLOGIST
Sub Investigator
AVE MARIA BIFFI, PSYCHOLOGIST
Sub Investigator
SILVIA BULLA, PSYCHOLOGIST
Sub Investigator
PAOLA PREVITALI, PSYCHOLOGIST
Sub Investigator
VERONICA FACCHINETTI, PSYCHOLOGIST
Sub Investigator
CRISTINA MORO, PSYCHOLOGIST
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.